In clinic studies, treatment with either CO-1686 or AZD9291 has resulted in more than 50% response rate in NSCLC patients bearing EGFR T790M, and are associated with substantially less skin toxicity than typically observed for first generation EGFR TKIs [17, 18]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.